

Date: 1 October 2017 4:57 pm

Topic: HRT Risks

HRT Risk

Risk	Age range (years)	Background incidence per 1000 women in Europe not using HRT		Additional cases per 1000 women using estrogen only HRT (estimated)		Additional cases per 1000 women using combined (estrogen-progestogen) HRT (estimated)	
		Over 5 years	Over 10 years	For 5 years' use	For 10 years' use	For 5 years' use	For 10 years' use
Breast cancer	50–59	10	20	2	6	6	24
	60–69	15	30	3	9	9	36
Endometrial cancer	50–59	2	4	4	32	NS	NS
	60–69	3	6	6	48	NS	NS
Ovarian cancer	50–59	2	4	<1	1	<1	1
	60–69	3	6	<1	2	<1	2
Venous thromboembolism	50–59	5		2		7	
	60–69	8		2		10	
Stroke	50–59	4		1		1	
	60–69	9		3		3	
Coronary heart disease	70–79	29–44		NS		15	

Note

Where background incidence or additional cases have not been included in the table, this indicates a lack of available data. NS indicates a non-significant difference

Taken from MHRA/CHM (*Drug Safety Update* 2007; 1 (2): 2–6) available at www.gov.uk/drug-safety-update

Note

The risk table does not apply to the combination of estrogen with the SERM bazedoxefine. The long term risks of this combination have not been established.